U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings

BioMarin Also Pausing Further Enrollment of Additional Participants Outside the U.S. in Phearless Phase 1/2 Study BioMarin is Working with FDA and Other Health Authorities and Will Communicate Next Steps When Available SAN RAFAEL, Calif., Sept. 6, 20... Biopharmaceuticals, FDA BioMarin Pharmaceutical, phenylalanine hydroxylase, phenylketonuria
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news